Pliant Therapeutics
WEBOur highly experienced team of fibrosis and drug development experts are claiming new territory in tissue-specific therapies. Pliant’s broad pipeline includes two clinical stage programs, including the first clinical stage, oral, selective small molecule integrin inhibitor.
Pliant Therapeutics Announces FDA Clearance of Investigational …
WEBPliant's lead product candidate, bexotegrast (PLN-74809), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or …
About - Pliant Therapeutics
WEBPliant Therapeutics is a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. As fibrosis is a complex disease, few available treatments for fibrosis exist today.
Pliant Therapeutics Provides Corporate Update and Reports Fourth ...
WEBPliant is currently conducting Phase 2a trials of bexotegrast in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis.
Pliant Therapeutics Reports Positive Interim Results from Phase 2a …
WEBPliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis. - Single dose administration of PLN-74809 achieved α v β 6 target engagement up to 98% in the lungs of IPF patients.
Pliant Therapeutics Provides Corporate Update and Reports Third …
WEBPliant's lead product candidate, PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or …
Pliant Therapeutics Announces Positive Long-Term Data from the …
WEBPliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or …
Pliant Therapeutics Announces Appointment of Lily Cheung as …
WEBSOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human Resources Officer. Ms. Cheung brings over 25 years of Human ...
Pliant Therapeutics Announces Closing of Upsized Public Offering …
WEBPliant is advancing its discovery and clinical stage portfolio by applying its deep understanding of fibrosis biology, medicinal chemistry, translational medicine and expertise integrin structure and biology.
Pliant Therapeutics Enters into $100 million Loan Facility …
WEBPliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809. PDF Version. Up to $100 million of non-dilutive capital from Oxford Finance LLC. Extends expected cash runway to mid-2024.